Chimeric Flavivirus Vaccine with Deleted Capsid Gene
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current flavivirus vaccines face challenges such as low potency, adverse reactions, and safety concerns, especially in immunocompromised individuals, and lack effective immunity against multiple serotypes, necessitating a more potent and safer vaccine technology.
Innovation Solution
Development of genetically engineered live-attenuated virus vaccines, specifically chimeric and trimeric flavivirus vaccines that include the membrane precursor gene (prM), envelope gene (E), and NS1 protein gene from a second flavivirus, which are designed to enhance immune response and reduce interference from pre-existing immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional inactivated viral vaccines are used, then vaccine production is established, but adverse events occur and potency is limited
Solution Approach 1:
The patent changes the fundamental parameter of vaccine architecture from inactivated whole virus to live-attenuated single-cycle virus. This transformation maintains the safety profile by preventing replication while enhancing potency through active immune stimulation. The single-cycle limitation parameter ensures the virus cannot replicate indefinitely, addressing safety concerns, while the live-attenuated nature provides robust immune responses.
Solution Approach 2:
The patent creates a composite vaccine system by engineering chimeric viruses that combine the safe backbone of one flavivirus (e.g., YF-17D) with the antigenic proteins (prM, E, NS1) of another flavivirus (e.g., dengue, West Nile, Japanese encephalitis). This composite structure provides both the safety of the parent virus and the protective immunity against the target pathogen.
2Productivity
If live-attenuated virus vaccines are used, then immune response is enhanced, but safety concerns arise in immunocompromised individuals
Solution Approach 1:
The patent introduces a critical parameter change by deleting the capsid (C) gene from the viral genome. This deletion renders the virus incapable of producing infectious particles, effectively limiting its replication cycle to a single round. This parameter modification maintains the live-attenuated virus's ability to stimulate robust immune responses while eliminating the safety risks associated with uncontrolled replication in immunocompromised individuals.
3Reliability
If vaccines target single serotypes, then specific immunity is achieved, but cross-protection against multiple serotypes is limited
Solution Approach 1:
The patent creates a universal vaccine platform where a single live-attenuated single-cycle virus vector can deliver antigens from multiple different flavivirus serotypes. The chimeric virus structure allows it to function against various flaviviruses (dengue, West Nile, Japanese encephalitis, yellow fever) by simply changing the inserted prM, E, and NS1 gene sequences, providing broad-spectrum protection through a single vaccine administration.
4Reliability
If pre-existing immunity is present, then prior protection exists, but interference with new vaccine response occurs
Solution Approach 1:
The patent segments the viral genome into distinct functional modules: a safe backbone structure from one flavivirus and separate antigen-encoding regions (prM, E, NS1) from target flaviviruses. This segmentation allows the vaccine to present foreign antigens that are distinct from pre-existing immunity targets, reducing interference while maintaining the safety of the vector backbone.
Data Source
AI summary
This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.